T
TCR2 Therapeutics Inc
F:2K7
TCR2 Therapeutics Inc
F:2K7
Price:
1.442
EUR
3.07%
Market Closed
Market Cap:
€56.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
T
|
TCR2 Therapeutics Inc
F:2K7
|
US |
|
Vertoz Advertising Ltd
NSE:VERTOZ
|
IN |
|
INCE Group PLC
LSE:INCE
|
UK |
|
P
|
Pan American Silver Corp
NYSE:PAAS
|
CA |
Cash Flow Statement
Cash Flow Statement
TCR2 Therapeutics Inc
TCR2 Therapeutics Inc
Currency: USD
| Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||||||||||
| Net Income |
(23)
|
(21)
|
(24)
|
(30)
|
(35)
|
(42)
|
(48)
|
(53)
|
(58)
|
(62)
|
(67)
|
(73)
|
(81)
|
(91)
|
(100)
|
(107)
|
(115)
|
(119)
|
(152)
|
(163)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
3
|
3
|
3
|
3
|
3
|
3
|
|
| Change in Deffered Taxes |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Other Non-Cash Items |
1
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
8
|
8
|
9
|
10
|
12
|
14
|
14
|
13
|
12
|
38
|
38
|
|
| Change in Working Capital |
2
|
2
|
3
|
1
|
(1)
|
(1)
|
(1)
|
(2)
|
(4)
|
(2)
|
1
|
2
|
5
|
4
|
2
|
(2)
|
6
|
5
|
10
|
12
|
|
| Cash from Operating Activities |
(20)
N/A
|
(17)
+16%
|
(19)
-13%
|
(27)
-42%
|
(32)
-21%
|
(37)
-17%
|
(41)
-10%
|
(47)
-13%
|
(53)
-12%
|
(54)
-1%
|
(57)
-6%
|
(60)
-6%
|
(63)
-5%
|
(72)
-14%
|
(82)
-14%
|
(93)
-14%
|
(93)
-1%
|
(100)
-7%
|
(101)
-2%
|
(110)
-9%
|
|
| Investing Cash Flow | |||||||||||||||||||||
| Capital Expenditures |
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(3)
|
(4)
|
(4)
|
(4)
|
(3)
|
(7)
|
(8)
|
(8)
|
(9)
|
(11)
|
(12)
|
(17)
|
(20)
|
(15)
|
(14)
|
|
| Other Items |
(19)
|
(20)
|
(75)
|
(132)
|
(112)
|
(96)
|
(17)
|
36
|
65
|
(25)
|
(42)
|
(6)
|
5
|
110
|
90
|
(44)
|
(94)
|
(89)
|
(73)
|
64
|
|
| Cash from Investing Activities |
(20)
N/A
|
(21)
-7%
|
(76)
-257%
|
(133)
-74%
|
(114)
+14%
|
(99)
+13%
|
(20)
+79%
|
32
N/A
|
61
+93%
|
(29)
N/A
|
(49)
-71%
|
(14)
+71%
|
(3)
+77%
|
101
N/A
|
78
-22%
|
(56)
N/A
|
(112)
-100%
|
(109)
+3%
|
(88)
+19%
|
51
N/A
|
|
| Financing Cash Flow | |||||||||||||||||||||
| Net Issuance of Common Stock |
141
|
141
|
125
|
85
|
80
|
79
|
80
|
(1)
|
(0)
|
134
|
135
|
266
|
266
|
133
|
133
|
1
|
1
|
0
|
0
|
0
|
|
| Net Issuance of Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(4)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other |
(0)
|
(1)
|
(2)
|
(2)
|
(3)
|
(1)
|
0
|
1
|
1
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Cash from Financing Activities |
141
N/A
|
140
-1%
|
123
-12%
|
82
-33%
|
77
-6%
|
78
+1%
|
80
+2%
|
0
-100%
|
0
+4 100%
|
134
+31 902%
|
135
+0%
|
262
+95%
|
266
+2%
|
132
-50%
|
132
0%
|
5
-96%
|
0
-90%
|
0
-56%
|
0
-42%
|
0
-28%
|
|
| Change in Cash | |||||||||||||||||||||
| Net Change in Cash |
102
N/A
|
103
+1%
|
28
-73%
|
(77)
N/A
|
(69)
+11%
|
(58)
+15%
|
18
N/A
|
(15)
N/A
|
9
N/A
|
52
+492%
|
29
-45%
|
188
+547%
|
200
+6%
|
162
-19%
|
129
-20%
|
(144)
N/A
|
(205)
-42%
|
(208)
-2%
|
(190)
+9%
|
(60)
+69%
|
|
| Free Cash Flow | |||||||||||||||||||||
| Free Cash Flow |
(21)
N/A
|
(18)
+16%
|
(20)
-12%
|
(27)
-39%
|
(33)
-21%
|
(41)
-22%
|
(45)
-11%
|
(51)
-13%
|
(57)
-11%
|
(57)
+0%
|
(64)
-12%
|
(68)
-7%
|
(72)
-5%
|
(81)
-13%
|
(93)
-15%
|
(105)
-13%
|
(111)
-6%
|
(120)
-8%
|
(117)
+2%
|
(124)
-6%
|
|
Switch to:
Switch to:
See Also
Discover More
